Stay updated on Switch to Dolutegravir + Rilpivirine Clinical Trial
Sign up to get notified when there's something new on the Switch to Dolutegravir + Rilpivirine Clinical Trial page.

Latest updates to the Switch to Dolutegravir + Rilpivirine Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.4.2 was added and Revision: v3.4.1 was removed. This is a minor metadata/version update and does not alter study details or page functionality.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision notice updated: added Revision: v3.4.1 and removed Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check41 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 in the page metadata.SummaryDifference0.0%

- Check62 days agoChange DetectedAdded Locations sections for California, District of Columbia, Florida, Georgia, Missouri, New Jersey, Texas, and Virginia and updated the page revision to v3.3.3. Removed HHS Vulnerability Disclosure and the California, District of Columbia, Florida, Georgia, Missouri, New Jersey, Texas, and Virginia Locations entries from the previous revision (v3.3.2).SummaryDifference0.5%

- Check91 days agoChange DetectedAdded a note clarifying that PubMed-published articles are auto-filled from PubMed and may not be about the study; Revision: v3.3.2 updated from the previous v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check99 days agoChange DetectedA site-wide government funding/operational status notice was removed from the page. This change does not affect the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Switch to Dolutegravir + Rilpivirine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switch to Dolutegravir + Rilpivirine Clinical Trial page.